ReviewFrontiers in cardiovascular medicine2025
Factor XI inhibitors are the novel promising anticoagulants in the treatment of age related thrombotic disease.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Brain-Atrial Fibrillation-Recent Rehabilitation Axis: A Modern Approach.Healthcare (Basel, Switzerland) · 2026Review
- Abelacimab for Acute Pulmonary Embolism: Translating Dual FXI/XIa Inhibition from Mechanism to Clinical Prospects.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence and mortality of thrombotic diseases in the aged population are increasing year by year, which seriously affect the quality of life of the elderly. At present, antithrombotic drugs used in clinical practice have good efficacy, but they caused different degrees of age-dependent bleeding risk. Therefore, there is an urgent need to develop effective antithrombotic drugs with less risk of bleeding. Recent studies have shown that factor Ⅺ inhibitors can effectively reduce the incidence of thromboembolic events without increasing the risk of bleeding. Therefore, factor Ⅺ inhibitors are expected to be safe and effective new anticoagulants, providing a new sight for the prevention and treatment of thrombotic diseases. This paper reviews the biological functions of factor Ⅺ, the types and characteristics of factor Ⅺ inhibitors and the related research progress of factor Ⅺ inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.